---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-003319"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:38:51.464282+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vaxart secures $105.9M BARDA funding increase; Phase 2b trial to test KP.2 vaccine vs mRNA

## Summary
- Total BARDA funding for the Phase 2b trial now $240.1M, up from $134.2M.
- Next trial portion will enroll 10,000 participants comparing Vaxart's KP.2 oral vaccine against an mRNA KP.2 comparator.
- Sentinel cohort of 400 (XBB vs mRNA XBB) completed; DSMB recommended proceed without modification.
- Vaxart awaiting BARDA approval to commence dosing in the KP.2 portion.
- Funding increase supports manufacturing of new KP.2 lots and expanded clinical activities.

## SEC filing metadata
- accession: 0001437749-25-003319
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925003319/0001437749-25-003319-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925003319/vxrt20250210_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-003319
- JSON: https://secwatch.observer/filing/0001437749-25-003319.json
- Plain text: https://secwatch.observer/filing/0001437749-25-003319.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.